See more : Ecoslops S.A. (ALESA.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Concord Medical Services Holdings Limited (CCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concord Medical Services Holdings Limited, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- ACON S2 Acquisition Corp. (STWO) Income Statement Analysis – Financial Results
- Oregon Pacific Bancorp (ORPB) Income Statement Analysis – Financial Results
- PCBL Limited (PCBL.NS) Income Statement Analysis – Financial Results
- TIM S.A. (TIMS3.SA) Income Statement Analysis – Financial Results
- Q-Free ASA (QFR.OL) Income Statement Analysis – Financial Results
Concord Medical Services Holdings Limited (CCM)
About Concord Medical Services Holdings Limited
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 537.40M | 472.09M | 485.63M | 223.01M | 198.36M | 190.90M | 330.98M | 455.04M | 616.49M | 606.88M | 563.12M | 455.65M | 450.13M | 389.52M | 292.44M | 171.79M |
| Cost of Revenue | 614.01M | 624.49M | 542.53M | 209.93M | 214.19M | 171.14M | 232.98M | 286.54M | 353.34M | 274.56M | 217.66M | 164.52M | 159.42M | 122.70M | 87.56M | 45.60M |
| Gross Profit | -76.61M | -152.41M | -56.90M | 13.08M | -15.83M | 19.76M | 98.00M | 168.50M | 263.15M | 332.32M | 345.47M | 291.13M | 290.71M | 266.82M | 204.88M | 126.19M |
| Gross Profit Ratio | -14.26% | -32.28% | -11.72% | 5.87% | -7.98% | 10.35% | 29.61% | 37.03% | 42.69% | 54.76% | 39.77% | 49.68% | 64.58% | 68.50% | 70.06% | 73.46% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 308.71M | 311.16M | 347.75M | 294.82M | 315.13M | 291.85M | 237.65M | 205.91M | 132.95M | 53.58M | 84.51M | 61.11M | 114.40M | 70.01M | 29.82M | 18.87M |
| Selling & Marketing | 56.30M | 61.48M | 53.68M | 25.76M | 30.24M | 21.72M | 43.61M | 70.09M | 112.82M | 95.10M | 104.67M | 53.91M | 37.45M | 17.15M | 7.68M | 5.50M |
| SG&A | 386.38M | 372.64M | 401.42M | 320.58M | 345.38M | 313.57M | 281.25M | 276.00M | 245.77M | 148.67M | 189.17M | 115.02M | 151.85M | 87.16M | 37.50M | 24.37M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 8.50M | 76.09M | 5.43M | 28.60M | 61.12M | 23.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 386.38M | 372.64M | 401.42M | 329.08M | 421.46M | 319.01M | 309.85M | 337.13M | 268.89M | 148.67M | 189.17M | 103.39M | 151.85M | 87.16M | 37.50M | 24.37M |
| Cost & Expenses | 1.00B | 997.13M | 943.95M | 539.01M | 635.66M | 490.14M | 542.83M | 623.67M | 622.23M | 423.23M | 406.83M | 267.92M | 311.27M | 209.86M | 125.06M | 69.96M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.60M | 13.36M | 7.87M | 948.00K | 430.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.45M | 7.45M | 6.89M | 7.46M |
| Depreciation & Amortization | 118.83M | 123.19M | 94.46M | 70.79M | 56.35M | 45.02M | 89.45M | 127.81M | 157.25M | 198.07M | 179.64M | 148.58M | 120.64M | 109.69M | 78.17M | 38.13M |
| EBITDA | -344.16M | -401.86M | -363.86M | -236.72M | -304.85M | -248.79M | -93.80M | 20.31M | 174.63M | 381.72M | 335.94M | 332.63M | -161.31M | 291.93M | 246.29M | 140.38M |
| EBITDA Ratio | -48.65% | -123.11% | -68.24% | -92.56% | -132.90% | -110.82% | -21.79% | 15.01% | 11.01% | 36.40% | 21.26% | 32.51% | 33.82% | 46.79% | 57.56% | 81.72% |
| Operating Income | -462.99M | -525.05M | -458.32M | -316.00M | -437.29M | -299.24M | -211.86M | -168.63M | -5.74M | 183.65M | 156.30M | 184.05M | 138.86M | 179.67M | 167.38M | 101.83M |
| Operating Income Ratio | -86.15% | -111.22% | -94.38% | -137.89% | -220.45% | -156.76% | -64.01% | -37.06% | -0.93% | 30.26% | 17.92% | 30.71% | 30.85% | 46.12% | 57.24% | 59.27% |
| Total Other Income/Expenses | -92.61M | -314.85M | -70.92M | -125.65M | 46.22M | 74.00M | -42.04M | -35.97M | 489.00K | -8.00M | -12.03M | -2.91M | -3.73M | -4.88M | -6.16M | 578.00K |
| Income Before Tax | -555.59M | -839.90M | -529.24M | -441.65M | -391.08M | -225.25M | -253.90M | -204.60M | -5.25M | 175.65M | 144.27M | 181.14M | -165.03M | 174.79M | 161.22M | 102.40M |
| Income Before Tax Ratio | -103.39% | -177.91% | -108.98% | -198.04% | -197.15% | -117.99% | -76.71% | -44.96% | -0.85% | 28.94% | 17.36% | 29.41% | -36.66% | 44.87% | 55.13% | 59.61% |
| Income Tax Expense | 24.57M | 70.91M | 6.57M | 37.62M | 38.99M | 34.05M | 31.79M | 60.49M | 74.03M | 80.85M | 63.84M | 54.25M | 46.32M | 43.87M | 36.40M | 23.34M |
| Net Income | -297.66M | -489.66M | -271.43M | -309.99M | -307.05M | -234.88M | -284.32M | -261.87M | -78.30M | 124.71M | 85.89M | 123.24M | -215.00M | 129.40M | 124.83M | 79.07M |
| Net Income Ratio | -55.39% | -103.72% | -168.98% | -300.39% | -278.54% | -188.18% | -85.90% | -57.55% | -12.70% | 16.35% | 13.34% | 27.05% | -47.77% | 33.22% | 42.69% | 46.03% |
| EPS | -68.14 | -112.09 | -187.85 | -153.35 | -127.27 | -82.83 | -65.57 | -60.14 | -17.46 | 22.08 | 16.69 | 2.67 | -4.53 | 2.67 | 1.86 | -25.89 |
| EPS Diluted | -68.14 | -112.09 | -187.85 | -153.35 | -127.27 | -82.83 | -65.57 | -60.14 | -17.46 | 21.95 | 16.69 | 2.67 | -4.53 | 2.67 | 1.86 | -25.89 |
| Weighted Avg Shares Out | 4.37M | 4.37M | 1.44M | 2.02M | 2.41M | 2.84M | 4.34M | 4.35M | 4.48M | 5.68M | 5.15M | 46.07M | 47.42M | 48.68M | 24.88M | 19.16M |
| Weighted Avg Shares Out (Dil) | 4.37M | 4.37M | 4.37M | 4.37M | 4.34M | 4.34M | 4.34M | 4.35M | 4.48M | 4.51M | 4.50M | 46.07M | 47.42M | 48.68M | 24.88M | 19.16M |
Reviewing 1life Healthcare (NASDAQ:ONEM) and Concord Medical Services (NASDAQ:CCM)
Report: Global Contrast Media Market Size & Share Will Reach USD 4,384.2 Million by 2026, Says Facts & Factors
Global Eukaryotic DNA Polymerase Market Size 2020 Global Industry Share, Revenue, Business Growth, Demand and Applications Market Research Report to 2026
American Shared Hospital Services (AMS) CEO Raymond Stachowiak on Q1 2020 Results - Earnings Call Transcript
Global Musculoskeletal Diseases Treatment Market 2020 Overview, Manufacturing Analysis, Segmentation, Development Status and Forecast to 2025
CA Forecast
US Forecast
Source: https://incomestatements.info
Category: Stock Reports